Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0YSPST
ADC Name
SC16.103-DL5
Synonyms
SC16.103 DL5; SC16.103DL5
   Click to Show/Hide
Organization
AbbVie, Inc.
Drug Status
Investigative
Indication
In total 1 Indication(s)
Small cell lung cancer [ICD11:2C25]
Investigative
Drug-to-Antibody Ratio
2
Structure
Antibody Name
SC16.103
  Antibody Info 
Antigen Name
Delta-like protein 3 (DLL3)
  Antigen Info 
Payload Name
SG3199
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Mc-PEG8-Val-Ala-PABC
  Linker Info 
Conjugate Type
Random conjugation through reduced inter-chain cysteines.
Combination Type
AbbVie's DL5
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.13
nM
HCC38 cells
Breast ductal carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.13 nM Positive CD276 expression (CD276 +++/++)
Method Description
The anti-tumor activity of these ADCs was tested in cytotoxicity assaysusing the HCC38 cell line. IC50 values were determined by quantitating viable cells using a CellTiter-Glo luminescent assay.
In Vitro Model Breast ductal carcinoma HCC38 cells CVCL_1267
References
Ref 1 Anti-b7-h3 antibodies and antibody drug conjugates; 2018-03-08.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.